As of November 6, 2026, Crinetics Pharmaceuticals, Inc. has been acquired by Vertex Pharmaceuticals Incorporated, as reported on Form 8-K on September 1, 2026. No bankruptcy or receivership appears in its SEC Form 8-K filings (Form 8-K, September 1, 2026).
Is this your company?
About to sign with, pay or invest in Crinetics Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Crinetics Pharmaceuticals, Inc. a real, registered company?
- Crinetics Pharmaceuticals, Inc. files with the SEC under CIK 1658247 (its SEC filings).
- It was acquired by Vertex Pharmaceuticals Incorporated (Form 8-K, 2026-09-01).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Crinetics Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 1 state WARN notice (latest 2026-11-03, San Diego CA, 78 employees).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Wellington Management (filed 2026-08-13).
Who are Crinetics Pharmaceuticals, Inc.'s owners and officers?
Crinetics Pharmaceuticals, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Form 8-K, 2026-09-01).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-03-11)
- : Executive Officer (Form D, 2024-03-11)
- : Director (Form D, 2024-03-11)
- : Director (Form D, 2024-03-11)
- : Director (Form D, 2024-03-11)
- : Director (Form D, 2024-03-11)
- : Director (Form D, 2024-03-11)
- : Director (Form D, 2024-03-11)
- : Director (Form D, 2024-03-11)
- : Executive Officer (Form D, 2024-03-11)
- : Executive Officer (Form D, 2024-03-11)
- : Executive Officer (Form D, 2024-03-11)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Wellington Management Group LLP | 6.8% |
| Schedule 13G/A, 2026-08-07 | Fmr LLC | 1.4% |
| Schedule 13G/A, 2026-08-03 | Farallon Capital Management, L.L.C. | 8.5% |
| Schedule 13G/A, 2026-05-15 | Driehaus Capital Management LLC | 6.11% |
| Schedule 13G/A, 2026-05-15 | Wellington Management Group LLP | 7.8% |
| Schedule 13G/A, 2026-05-15 | T. Rowe Price Associates, Inc. | 5.1% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.19% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-05 | Dapice Joshua J. | 8.5% |
| Schedule 13G/A, 2025-11-12 | Wellington Management Group LLP | 8.9% |
| Schedule 13G, 2025-09-08 | Dapice Joshua J. | 6% |
| Schedule 13G/A, 2025-08-12 | Wellington Management Group LLP | 6.2% |
Questions about who owns Crinetics Pharmaceuticals, Inc.
Who owns Crinetics Pharmaceuticals, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Crinetics Pharmaceuticals, Inc.: Farallon Capital Management, L.L.C. (8.5%, Schedule 13G/A, filed 2026-08-03), Dapice Joshua J. (8.5%, Schedule 13G/A, filed 2026-02-05), Wellington Management Group LLP (6.8%, Schedule 13G/A, filed 2026-08-13), Driehaus Capital Management LLC (6.11%, Schedule 13G/A, filed 2026-05-15) and Vanguard Capital Management (5.19%, Schedule 13G, filed 2026-04-29); 1 more is listed above.
Who are the largest shareholders of Crinetics Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Crinetics Pharmaceuticals, Inc. on this page are Farallon Capital Management, L.L.C. (8.5%), Dapice Joshua J. (8.5%) and Wellington Management Group LLP (6.8%).
When did Farallon Capital Management, L.L.C. buy into Crinetics Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Farallon Capital Management, L.L.C. on this page is the Schedule 13G/A, filed 2026-08-03, reporting 8.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Crinetics Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Crinetics Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Crinetics Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has Crinetics Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-03-11 | $350M | $350M |
Acquisitions reported on Form 8-K, Item 2.01: acquired by Vertex Pharmaceuticals Incorporated (2026-09-01).
Keep reading
More on Crinetics Pharmaceuticals, Inc. and the records around it.
Crinetics Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Cue Biopharma, Inc. (Aug 2026), Definium Therapeutics, Inc. (Aug 2026)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: ENANTA PHARMACEUTICALS INC (Aug 2026), EXELIXIS, INC. (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/crinetics-pharmaceuticals